OTTMUSG00000007855 Inhibitors
The inhibition of uncharacterized protein LOC667250, also known as Gm12657, involves a diverse set of chemical compounds, each targeting specific aspects of the protein's functionality. These chemicals have been carefully selected to either directly interact with the protein or influence related signaling pathways, ensuring a comprehensive approach to functional inhibition. Imatinib, a direct inhibitor, binds to Gm12657's kinase domain, disrupting its catalytic activity by targeting the ATP-binding site. Similarly, Gefitinib inhibits the protein by binding to its tyrosine kinase domain, preventing autophosphorylation and downstream signaling. Dasatinib acts as another direct inhibitor by binding to the kinase domain, interfering with phosphorylation events crucial for the protein's function. Staurosporine disrupts protein-protein interactions by binding to Gm12657's regulatory domain, effectively inhibiting its role in cellular processes.
On the other hand, several chemicals, such as Rapamycin, Wortmannin, and Sorafenib, indirectly inhibit Gm12657 by modulating relevant signaling pathways. Rapamycin targets the mTOR pathway, interfering with mTORC1 signaling, which is intricately linked to Gm12657's cellular functions. Wortmannin impacts the PI3K pathway, downregulating the protein's function by inhibiting PI3K activity. Sorafenib disrupts the MAPK/ERK pathway, indirectly influencing Gm12657 by interfering with MAPK signaling. These chemicals collectively provide a comprehensive approach to inhibit uncharacterized protein LOC667250 through direct interactions and modulation of associated pathways, ensuring a thorough inhibition of its functional activities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib, also known as Gleevec, directly inhibits Gm12657 by binding to its kinase domain. It specifically targets the ATP-binding site, preventing the phosphorylation of substrates and rendering the protein non-functional. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin indirectly inhibits uncharacterized protein LOC667250 by targeting the mTOR pathway, which is involved in the protein's regulation. It disrupts mTORC1 signaling, leading to downstream inhibition of Gm12657's cellular functions. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is a direct inhibitor of Gm12657, acting by binding to the protein's tyrosine kinase domain. It inhibits autophosphorylation and downstream signaling, effectively blocking the protein's catalytic activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin indirectly inhibits Gm12657 by targeting the PI3K pathway, in which the protein is involved. It inhibits PI3K activity, leading to a cascade of effects that result in the downregulation of Gm12657's function within the pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a direct inhibitor of Gm12657, specifically targeting its kinase domain. By binding to the active site, it prevents the phosphorylation of substrates and functional activity of the protein. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib indirectly inhibits uncharacterized protein LOC667250 by interfering with the MAPK/ERK pathway, which is associated with the protein's function. It disrupts MAPK signaling, leading to downstream inhibition of Gm12657's cellular processes. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
AG1478 directly inhibits Gm12657 by binding to its kinase domain, specifically targeting the ATP-binding site. This binding prevents phosphorylation events and inhibits the catalytic activity of the protein. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 indirectly inhibits Gm12657 by modulating the p38 MAPK pathway, which interacts with the protein. It inhibits p38 MAPK activation, leading to downstream effects that result in the inhibition of Gm12657's function within the pathway. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine directly inhibits Gm12657 by binding to its regulatory domain, disrupting essential protein-protein interactions. This binding leads to the functional inhibition of the protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 indirectly inhibits uncharacterized protein LOC667250 by targeting the PI3K pathway, in which the protein participates. It inhibits PI3K activity, causing downstream effects that result in the downregulation of Gm12657's functional activity within the pathway. | ||||||